破伤风类毒素疫苗市场规模- 按疫苗类型（破伤风类毒素(TT)、白喉和破伤风(DT)、破伤风和白喉(Td)、五价和白喉、破伤风和百日咳(DTaP)）、年龄组（儿童、成人）），最终用途和预测，2024 - 2032

Tetanus Toxoid Vaccine Market Size - By Vaccine Type (Tetanus Toxoid (TT), Diphtheria and Tetanus (DT), Tetanus and Diphtheria (Td), Pentavalent, & Diphtheria, Tetanus, and Pertussis (DTaP)), Age Group (Pediatric, Adult), End-use & Forecast, 2024 - 2032

出版日期: 2024年02月28日 | 出版商:

Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于人们对疫苗接种重要性的认识不断提高、免疫计划的扩大以及疫苗开发和分配基础设施的进步，破伤风类毒素疫苗市场规模预计在2024 年至2032 年期间将以超过5.8% 的复合年增长率增长。

根据我们的数据世界，破伤风每年夺走全球约 5 万人的生命，对卫生条件差和疫苗接种覆盖率不足的地区造成的影响尤为严重。与破伤风相关的死亡和残疾人数不断增加，凸显了广泛免疫工作的迫切需求。随着人们对破伤风相关风险的认识不断增强，医疗机构和政府正在加紧努力，扩大疫苗接种计划并提高疫苗的可及性。对破伤风预防的高度重视正在推动全球对破伤风类毒素疫苗的需求。此外，医疗保健组织和倡导团体正在积极推动疫苗接种运动，以教育社区了解免疫接种在预防破伤风感染和降低死亡率方面的重要性。

破伤风类毒素疫苗市场按疫苗类型、年龄层、最终用途和地区分类。

由于破伤风类毒素 (TT) 疫苗类型在常规免疫计划和大规模疫苗接种活动中的广泛使用，预计 2024 年至 2032 年的复合年增长率将达到 5.4%。 TT 疫苗对于预防破伤风非常有效，破伤风是一种由破伤风梭菌引起的潜在致命疾病。这些疫苗也透过刺激人体的免疫反应产生针对破伤风毒素的保护性抗体来诱发免疫力，从而赋予针对疾病的持久免疫力。

预计到2032 年，成人年龄层的破伤风类毒素疫苗市场复合年增长率将达到5.3%。中，例如医疗机构、建筑业地点和农田。此外，人口老化和削弱免疫系统的慢性疾病的流行凸显了成年人接种破伤风疫苗的必要性，以预防与破伤风相关的併发症和死亡。

在人口成长、快速城市化和医疗基础设施改善的推动下，亚太地区破伤风类毒素疫苗产业预计到 2032 年复合年增长率将达到 6.3%。印度、中国和东南亚国家在医疗保健和免疫计画方面进行了大量投资，推动了对破伤风类毒素疫苗的需求。此外，扩大免疫计画（EPI）和在国家免疫计画中引入含破伤风类毒素的疫苗等措施也有助于区域市场的扩张。

产业生态系统分析
产业影响力
- 成长动力
  - 已开发国家加大疫苗研发力度
  - 一些国家破伤风和白喉病例不断增加
  - 增加政府疫苗接种倡议计划
  - 类毒素疫苗研发的技术进展
- 产业陷阱与挑战
  - 与类毒素疫苗相关的副作用
成长潜力分析
技术景观
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
竞争定位矩阵
战略展望矩阵

第 5 章：市场估计与预测：按疫苗类型，2018 年 - 2032 年

主要趋势
破伤风类毒素 (TT)
白喉和破伤风 (DT)
破伤风和白喉 (Td)
白喉、破伤风和百日咳 (DTaP)
破伤风、白喉和百日咳 (Tdap)
白喉、破伤风、百日咳、Hib 和B型肝炎 (DTP-Hib-HepB)
五价 (DTaP-IPV/Hib)
六价 (DTaP-IPV/Hib-HepB)
其他疫苗类型

第 6 章：市场估计与预测：按年龄划分，2018 - 2032

主要趋势
儿科
成人

第 7 章：市场估计与预测：按最终用途，2018 - 2032 年

主要趋势
医院和诊所
政府机构
其他最终用户

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Bharat Biotech International Limited
Biological E. Limited
Biological Products Institute (BPI) Argentina
Chengdu Institute of Biological Products Co., Ltd.
GlaxoSmithKline
Johnson & Johnson
Merck & Co., Inc.
Mitsubishi Tanabe Pharma Corporation
Panacea Biotec Limited
Pfizer Inc.
Sanofi
Serum Institute of India
Zydus Group

简介目录

Product Code: 8301

Tetanus Toxoid Vaccine Market size is expected to grow at more than 5.8% CAGR during 2024-2032, driven by rising awareness about the importance of vaccination, expanding immunization programs, and advances in vaccine development and distribution infrastructure.

According to Our World in Data, Tetanus claims approximately 50,000 lives globally each year, with a disproportionate impact on regions characterized by poor sanitation and inadequate vaccination coverage. This increasing number of tetanus-related deaths and disabilities is underscoring the urgent need for widespread immunization efforts. As awareness about the risks associated with tetanus grows, healthcare authorities and governments are intensifying their efforts to expand vaccination programs and improve vaccine accessibility. This heightened focus on tetanus prevention is driving the demand for tetanus toxoid vaccines globally. Moreover, healthcare organizations and advocacy groups are actively promoting vaccination campaigns to educate communities about the importance of immunization in preventing tetanus infections and reducing mortality rates.

The tetanus toxoid vaccine market is classified into vaccine type, age group, end-use and region.

The market size from the tetanus toxoid (TT) vaccine type segment is anticipated to record 5.4% CAGR from 2024 to 2032, due to their widespread use in routine immunization programs and mass vaccination campaigns. TT vaccines are highly effective in preventing tetanus, a potentially fatal disease caused by the bacterium Clostridium tetani. These vaccines also induce immunity by stimulating the body's immune response to produce protective antibodies against the tetanus toxin, thereby conferring long-lasting immunity against the disease.

Tetanus toxoid vaccine market from the adult age group segment is expected to witness 5.3% CAGR through 2032. The growth is driven by increasing awareness among adults about the importance of tetanus vaccination, particularly in high-risk occupational settings, such as healthcare facilities, construction sites, and agricultural fields. Additionally, the aging population and the prevalence of chronic medical conditions that weaken the immune system are underscoring the need for tetanus vaccination among adults to prevent tetanus-related complications and fatalities.

Asia Pacific tetanus toxoid vaccines industry is poised to record 6.3% CAGR up to 2032, fueled by population growth, rapid urbanization, and improving healthcare infrastructure. India, China, and Southeast Asian nations are witnessing significant investments in healthcare and immunization programs, driving the demand for tetanus toxoid vaccines. Furthermore, initiatives, such as the Expanded Program on Immunization (EPI) and the introduction of tetanus toxoid-containing vaccines in national immunization schedules are contributing to the regional market expansion.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increase in vaccines research and development in developed nations
  - 3.2.1.2 Growing cases of tetanus and diphtheria in some countries
  - 3.2.1.3 Increasing government initiatives programs for vaccination
  - 3.2.1.4 Technological advancemen in development of toxoid vaccine
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side-effects associated with toxoid vaccine
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
- 3.6.1 Supplier power
- 3.6.2 Buyer power
- 3.6.3 Threat of new entrants
- 3.6.4 Threat of substitutess
- 3.6.5 Industry rivalry
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategic outlook matrix

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Tetanus toxoid (TT)
5.3 Diphtheria and tetanus (DT)
5.4 Tetanus and diphtheria (Td)
5.5 Diphtheria, tetanus, and pertussis (DTaP)
5.6 Tetanus, diphtheria, and pertussis (Tdap)
5.7 Diphtheria, tetanus, pertussis, Hib and hepatitis B (DTP-Hib-HepB)
5.8 Pentavalent (DTaP-IPV/Hib)
5.9 Hexavalent (DTaP-IPV/Hib-HepB)
5.10 Other vaccine types

Chapter 6 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Pediatric
6.3 Adult

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals and clinics
7.3 Government organizations
7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa